Is Arcutis Biotherapeutics Inc. (NASDAQ:ARQT) an excellent stock to buy at the moment?

The price of Arcutis Biotherapeutics Inc. (NASDAQ: ARQT) closed at $16.24 in the last session, up 4.44% from day before closing price of $15.55. In other words, the price has increased by $+0.69 from its previous closing price. On the day, 1185918 shares were traded. ARQT stock price reached its highest trading level at $16.35 during the session, while it also had its lowest trading level at $15.44.

Will You Miss Out On This Growth Stock Boom?

A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.

And this is just one of our 5 Best Growth Stocks To Own For 2023.



We take a closer look at ARQT’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 13.30 and its Current Ratio is at 13.40. In the meantime, Its Debt-to-Equity ratio is 0.73 whereas as Long-Term Debt/Eq ratio is at 0.73.

Upgrades & Downgrades

In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Needham on September 07, 2022, initiated with a Buy rating and assigned the stock a target price of $46.

On March 17, 2022, Goldman started tracking the stock assigning a Buy rating and target price of $45.

On June 30, 2021, Mizuho started tracking the stock assigning a Buy rating and target price of $58.Mizuho initiated its Buy rating on June 30, 2021, with a $58 target price.

Insider Transactions:

An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Jan 17 when Welgus Howard G. sold 8,500 shares for $13.72 per share. The transaction valued at 116,655 led to the insider holds 165,825 shares of the business.

Burnett Patrick sold 1,475 shares of ARQT for $22,136 on Jan 03. The insider now owns 41,564 shares after completing the transaction at $15.01 per share. On Dec 07, another insider, Watanabe Todd Franklin, who serves as the insider of the company, sold 1,000 shares for $17.06 each. As a result, the insider received 17,060 and left with 378,907 shares of the company.

Valuation Measures:

For the stock, the TTM Price-to-Sale (P/S) ratio is 1353.49 while its Price-to-Book (P/B) ratio in mrq is 3.43.

Stock Price History:

Over the past 52 weeks, ARQT has reached a high of $27.40, while it has fallen to a 52-week low of $12.81. The 50-Day Moving Average of the stock is 16.34, while the 200-Day Moving Average is calculated to be 19.86.

Shares Statistics:

According to the various share statistics, ARQT traded on average about 814.94K shares per day over the past 3-months and 997.69k shares per day over the past 10 days. A total of 60.93M shares are outstanding, with a floating share count of 58.93M. Insiders hold about 1.40% of the company’s shares, while institutions hold 98.40% stake in the company. Shares short for ARQT as of Oct 13, 2022 were 6.85M with a Short Ratio of 10.65M, compared to 5.2M on Sep 14, 2022. Therefore, it implies a Short% of Shares Outstanding of 11.39% and a Short% of Float of 18.27%.

Earnings Estimates

The company has 8 analysts who recommend its stock at the moment. On average, analysts expect EPS of -$1.54 for the current quarter, with a high estimate of -$1.26 and a low estimate of -$1.92, while EPS last year was -$1.14. The consensus estimate for the next quarter is -$1.38, with high estimates of -$1.23 and low estimates of -$1.62.

Analysts are recommending an EPS of between -$5.24 and -$5.86 for the fiscal current year, implying an average EPS of -$5.55. EPS for the following year is -$4.42, with 9 analysts recommending between -$3.47 and -$5.28.

Revenue Estimates

Based on 9 analysts’ estimates, the company’s revenue will be $57.21M in the next fiscal year. The high estimate is $80.6M and the low estimate is $20.7M. The average revenue growth estimate for next year is up 1,644.20% from the average revenue estimate for this year.